NTAD: A longitudinal neuroimaging dataset of Alzheimer's disease pathology

Abstract

We introduce the New Therapeutics in Alzheimer's Disease (NTAD) dataset, a multi-modal and longitudinal imaging dataset from 70 biomarker-positive people with early dementia or Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD), assessed over 2.5 years, and 35 healthy controls assessed at baseline. The data include simultaneous magneto- and electro-encephalography (M/EEG), 3-Tesla structural and functional magnetic resonance imaging (MRI), Amyloid-beta; positron emission tomography (PET), fluid proteomic biomarkers in cerebrospinal fluid and blood, and a battery of clinical and neuropsychological assessments. 11C UCB-J PET was undertaken for a subset of participants. For people with AD, assessments were repeated at approximately three weeks, 15 months, and 28 months after baseline. The data can be accessed through the Dementias Platform UK (DPUK), including pre-processed M/EEG and T1 MRI in pseudonymised BIDS format. With the pressing need to develop treatments for slowing, reversing, and preventing AD, these data provide an opportunity for identifying and validating novel biomarkers of Alzheimer's disease neurophysiology, as well as understanding its treatable pathology.

Interpretable Machine Learning Links Group-Specific Plasma Proteomics to Regional Structural Neuroimaging in Alzheimer's Disease
H. Laugi, M. Hosseinzadehketilateh, S. Lee +2
bioRxiv2 Nov 2026PreprintAll rights reservedFull textNeurosciencebioRxiv
Cross-Dataset Reanalysis of Mouse Alzheimer Disease Single-Cell RNA-Sequencing Data Reveals a Reproducible Innate Immune Activation Signature
A. Anand, E. Natarajan
bioRxiv30 Sep 2026PreprintAll rights reservedFull textBioinformatics & computational biologybioRxiv
BNIP3L/NIX-mediated mitophagy limits Alzheimer disease pathology and preserves neuronal function
Y. Li, C. Ploumi, C. Volbracht +17
bioRxiv18 Oct 2026PreprintCC BY-NDFull textCell biologybioRxiv
Citrus leaf pathology multi-class image dataset and a hybrid multi-branch attention fusion network for lemon leaf disease classification
Chayan Mondal Abir, Subir Biswas, Prabodh Kumar Sahoo +1
Scientific Reports14 Oct 2026Peer-reviewedCC BY 4.0Full textPlant biologyCrossref
Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology
Vaibhav Vemuganti, Jea Woo Kang, Qijun Zhang +21
Nature Communications26 Jun 2026Peer-reviewedCC BY7 citedNeuroscienceOpenAlex

Cite

BibTeX RIS

BibTeX

@misc{es2026ntad,
  title = {{NTAD: A longitudinal neuroimaging dataset of Alzheimer's disease pathology}},
  author = {M. W. J. van Es and M. N. Perquin and A. J. Quinn and J. Pitt and A. Krugliak and T. Thayanandan and J. Lanskey and E. Kocagoncu and M. Karadag and C. Alcock and M. Naessens and S. Lowe and H. Fye and V. Raymont and K. D. Singh and R. N. Henson and A. C. Nobre and M. W. Woolrich and J. Rowe and the NTAD study group},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.30.763020},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.30.763020v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - NTAD: A longitudinal neuroimaging dataset of Alzheimer's disease pathology
AU  - M. W. J. van Es
AU  - M. N. Perquin
AU  - A. J. Quinn
AU  - J. Pitt
AU  - A. Krugliak
AU  - T. Thayanandan
AU  - J. Lanskey
AU  - E. Kocagoncu
AU  - M. Karadag
AU  - C. Alcock
AU  - M. Naessens
AU  - S. Lowe
AU  - H. Fye
AU  - V. Raymont
AU  - K. D. Singh
AU  - R. N. Henson
AU  - A. C. Nobre
AU  - M. W. Woolrich
AU  - J. Rowe
AU  - the NTAD study group
PY  - 2026
DA  - 2026/10/30
PB  - bioRxiv
DO  - 10.64898/2026.10.30.763020
UR  - https://www.biorxiv.org/content/10.64898/2026.10.30.763020v1
AB  - We introduce the New Therapeutics in Alzheimer's Disease (NTAD) dataset, a multi-modal and longitudinal imaging dataset from 70 biomarker-positive people with early dementia or Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD), assessed over 2.5 years, and 35 healthy controls assessed at baseline. The data include simultaneous magneto- and electro-encephalography (M/EEG), 3-Tesla structural and functional magnetic resonance imaging (MRI), Amyloid-beta; positron emission tomography (PET), fluid proteomic biomarkers in cerebrospinal fluid and blood, and a battery of clinical and neuropsychological assessments. 11C UCB-J PET was undertaken for a subset of participants. For people with AD, assessments were repeated at approximately three weeks, 15 months, and 28 months after baseline. The data can be accessed through the Dementias Platform UK (DPUK), including pre-processed M/EEG and T1 MRI in pseudonymised BIDS format. With the pressing need to develop treatments for slowing, reversing, and preventing AD, these data provide an opportunity for identifying and validating novel biomarkers of Alzheimer's disease neurophysiology, as well as understanding its treatable pathology.
ER  -

Abstract

Related

Cite